Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
2.
Gastroenterol Clin Biol ; 30(4): 594-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16733384

ABSTRACT

OBJECTIVES: Restorative proctocolectomy with ileoanal anastomosis (IPAA) is the surgical standard for patients with ulcerative colitis (UC). Significant reduction in female fertility and fecundity after IPAA has been shown in recent studies. In selected cases, colectomy with ileorectal anastomosis (IRA) is another surgical option. The aim of this study was to evaluate fertility in women with UC who underwent IRA. PATIENTS AND METHODS: This study included all women with UC who underwent IRA between 1962 and 1999 and who were 40 years old or younger at the time of surgery, and older than 18 years of age at the time of the interview. Data were collected using a structured telephone interview concerning reproductive behavior and waiting times to pregnancy. RESULTS: Among 40 eligible patients, 37 whose mean age at IRA was 28 years (range 11-39) answered the questionnaire. Twenty-two were unmarried, not wishful of pregnancy and/or already had children. Among 15 females wishing children after IRA, 10 (66%) became pregnant: one had therapeutic abortion, two had a miscarriage, four had 1 child, two had 2 children and one had 4 children. Five patients were sterile after IRA. CONCLUSION: These preliminary results suggest that IRA for UC preserves female fertility. If confirmed in other series this information should be provided to young women with UC before deciding surgical option.


Subject(s)
Colectomy/methods , Colitis, Ulcerative/surgery , Fertility , Ileum/surgery , Rectum/surgery , Adult , Anastomosis, Surgical , Female , Follow-Up Studies , Humans , Infertility, Female/prevention & control , Pregnancy , Pregnancy Outcome
3.
Oncology ; 70(2): 154-8, 2006.
Article in English | MEDLINE | ID: mdl-16645329

ABSTRACT

OBJECTIVES: We assessed the safety and efficacy of docetaxel, a microtubule inhibitor, in patients with advanced hepatocellular carcinoma (HCC). METHODS: HCC patients that were not suitable for local therapy, but who possessed measurable disease, good performance status and adequate organ function were eligible. Docetaxel was administered every 3 weeks at a dose of 100 mg/m(2) (or 75 mg/m(2) if transaminase levels were between 1.5 and 3.5 times the upper normal limit). Efficacy was assessed radiologically every three cycles of chemotherapy. RESULTS: Fifteen patients were enrolled: 11 males and 4 females; their median age was 64 years (range, 42-72 years). Nine patients had underlying cirrhosis. Four patients had been surgically treated before relapse (liver resection in 3 cases and transplantation in 1), 3 had been treated with arterial chemoembolization and 1 with arterial chemotherapy (doxorubicin). A total of 57 cycles of docetaxel were delivered (median 3, range 1-6). Significant toxicity was observed: mostly grade 3-4 neutropenia and fatigue (6 and 4 patients, respectively). Treatment had to be stopped because of toxicity in 6 patients, all having underlying cirrhosis. An important partial response was obtained in 1 patient, a result that enabled liver transplantation; this patient is still alive after 34 months. Five patients had transient stable disease. CONCLUSION: When used in this schedule, docetaxel does not appear to be safe and effective enough in patients with advanced HCC and cirrhosis.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Taxoids/therapeutic use , Adult , Aged , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Carcinoma, Hepatocellular/secondary , Disease-Free Survival , Docetaxel , Drug Administration Schedule , Female , Humans , Liver Cirrhosis/complications , Liver Neoplasms/pathology , Male , Middle Aged , Survival Analysis , Taxoids/administration & dosage , Taxoids/adverse effects , Treatment Failure
4.
Gastroenterol Clin Biol ; 30(2): 314-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16565670

ABSTRACT

Abdominal trauma is a classic but very rare cause of portal vein thrombosis. We report the case of a patient with portal vein thrombosis and cavernoma associated with portal hypertension. Anamnesis identified a serious thoraco-abdominal trauma related to a bicycle accident 6 months before. Biological screening identified an inherited heterozygous G20210A factor II gene mutation which supports a recent notion that portal vein thrombosis most often occurs when both local and systemic aetiological factors are combined.


Subject(s)
Abdominal Injuries/complications , Portal Vein , Venous Thrombosis/etiology , Adult , Anticoagulants/therapeutic use , Humans , Male , Mutation , Prothrombin/genetics , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy
6.
Gastroenterol Clin Biol ; 29(8-9): 931-2, 2005.
Article in French | MEDLINE | ID: mdl-16294164

ABSTRACT

Eosinophilic gastroenteritis is an uncommon disease with an unknown natural history, and its relation to digestive allergies has not been confirmed. This study reports the case of a 27 year old patient who developed eosinophilic gastroenteritis with gastric, intestinal, rectal and peritoneal localisations. In the Congo, massive blood hypereosinophilia suggests digestive parasitosis and gastroenteritis with malnutrition and cutaneous symptoms suggest AIDS/HIV, making the present agnosis uncommon.


Subject(s)
Eosinophilia/diagnosis , Gastroenteritis/diagnosis , Tropical Climate , Abdominal Pain/etiology , Adrenal Cortex Hormones/therapeutic use , Adult , Congo , Diarrhea/etiology , Eosinophilia/drug therapy , Female , Gastroenteritis/drug therapy , Humans , Vomiting/etiology
7.
Gastroenterol Clin Biol ; 29(6-7): 664-6, 2005.
Article in English | MEDLINE | ID: mdl-16142000

ABSTRACT

AIM OF THE STUDY: To assess the prevalence of risk factors of prion-related disease transmission in a gastrointestinal endoscopy unit. METHODS: Clinical evaluation of the risk of transmission of prion-related diseases using the criteria defined by the French circular 138 in patients referred for digestive endoscopy without anesthesia. RESULTS: 1017 patients were included in this study. According to circular 138, 7 patients (0.68%) were at high risk of transmitting prion-related disease. According to these criteria, a high index of suspicion of prion-related disease was detected in 26 patients (2.55%). Clinical evaluation of risk was not possible for 56 patients (5.51%), due to coma or sedation (38 patients) or communication impairment (18 patients). CONCLUSIONS: Application of circular 138 led us to consider that 2.55% of patients in this study had a high risk of prion-related disease. The circular criteria cannot be assessed in patients with sedation for mechanical ventilation, coma or communication impairment.


Subject(s)
Endoscopy, Gastrointestinal/statistics & numerical data , Female , Humans , Male , Middle Aged , Prevalence , Prion Diseases , Prospective Studies , Referral and Consultation , Risk Factors
9.
Gastroenterology ; 128(2): 334-42, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15685545

ABSTRACT

BACKGROUND AND AIMS: Liver inflammation, fibrosis, and dyslipidemia are common features in patients with chronic hepatitis C virus (HCV) infection. Because peroxisome proliferator-activated receptor alpha (PPARalpha) is highly expressed in the liver and is involved in the regulation of lipid metabolism and inflammation, we sought to determine whether HCV infection may locally impair PPARalpha expression and activity. METHODS: PPARalpha expression was investigated in liver biopsy specimens of 86 untreated patients with HCV infection and controls, by using real-time polymerase chain reaction (PCR), Western blot analysis, and immunohistochemistry. PPARalpha activity was assessed by quantification of the key gene target carnitine palmitoyl acyl-CoA transferase 1 (CPT1A) messenger RNA (mRNA). The influence of HCV core protein on PPARalpha mRNA expression was analyzed in vitro by real-time PCR in HCV core-expressing HepG2 cells activated with the PPARalpha ligand fenofibric acid. RESULTS: Hepatic concentrations of PPARalpha and CPT1A expressed by hepatocytes were impaired profoundly in the livers of untreated patients with HCV infection compared with controls. A mean decrease of 85% in PPARalpha mRNA expression paralleled with a lack of CPT1A mRNA induction also were observed in HCV core-expressing HepG2 cells compared with controls. CONCLUSIONS: HCV infection is related to altered expression and function of the anti-inflammatory nuclear receptor PPARalpha. These results identify hepatic PPARalpha as one mechanism underlying the pathogenesis of HCV infection, and as a new therapeutic target in traditional treatment of HCV-induced liver injury.


Subject(s)
Fenofibrate/analogs & derivatives , Gene Expression Regulation/physiology , Hepatitis C, Chronic/pathology , PPAR alpha/genetics , Biopsy , Carcinoma, Hepatocellular , Cell Line , DNA Primers , Fenofibrate/pharmacology , Humans , Immunohistochemistry , Liver/pathology , Liver Neoplasms , Transcription, Genetic/drug effects , Transfection
10.
J Hepatol ; 41(3): 462-73, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15336450

ABSTRACT

BACKGROUND/AIMS: The benefit of amantadine combination therapy, either with interferon (IFN) alone (double therapy) or with ribavirin and IFN (triple therapy) is unknown. METHODS: We analyzed the effect of amantadine on the end-of-treatment virological response and the sustained response using meta-analysis of 31 randomized controlled trials. RESULTS: Overall analysis revealed a significant effect of amantadine. Triple therapy was the best regimen for improving the sustained response (mean difference: 8.4%, 95% CI: 2.4-13.8%, P=0.002). In subgroup analysis, amantadine did not have a significant effect upon naive patients or relapsers. In non-responders, combination therapy with amantadine was associated with a significant effect on the sustained response (mean difference: 8.3%, 95% CI: 1.9-14.6%, P=0.01). In sensitivity analysis, double therapy did not improve virological responses. Conversely, triple therapy tended to improve the end-of-treatment virological response and was associated with a significant effect upon the sustained response (mean difference: 12.7%, 95% CI: 3.8-21.6%, P=0.005). CONCLUSIONS: Combination therapy with amantadine is of no effect upon naive patients or relapsers. In non-responders, triple therapy with amantadine improved the sustained response. New randomized controlled trials are required to confirm this meta-analysis.


Subject(s)
Amantadine/therapeutic use , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Amantadine/administration & dosage , Antiviral Agents/administration & dosage , Humans , Interferon Type I/administration & dosage , Randomized Controlled Trials as Topic , Recombinant Proteins , Ribavirin/administration & dosage
11.
Gastroenterol Clin Biol ; 28(6-7 Pt 1): 605-7, 2004.
Article in French | MEDLINE | ID: mdl-15243396

ABSTRACT

We report the case of a 65-Year-old man with advanced hepatocellular carcinoma related to alcoholic cirrhosis who was hospitalised for oliguric renal failure. Investigations showed a severe nephrotic syndrome related to paraneoplastic membranous glomerulonephritis. The patient's course was temporarily stabilized with loop diuretics and dialysis but the patient died of hemoperitoneum from a ruptured tumor.


Subject(s)
Carcinoma, Hepatocellular/complications , Glomerulonephritis, Membranous/etiology , Liver Neoplasms/complications , Aged , Carcinoma, Hepatocellular/etiology , Fatal Outcome , Hemoperitoneum/etiology , Humans , Liver Cirrhosis/complications , Liver Neoplasms/etiology , Male , Renal Insufficiency/etiology
15.
Liver Transpl ; 9(4): 394-400, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12682893

ABSTRACT

The purpose of this study was to evaluate the results of percutaneous transhepatic management (PTM) of anastomotic biliary strictures (BS). Among 168 liver transplant adult recipients, BS was identified in 30 patients. In 6 patients, narrowing of the anastomosis was found early, and in all cases disappeared spontaneously with prolonged draining of the bile tube. Within a mean time of 14 months after transplantation, 24 patients had symptomatic BSs, revealed by cholestasis (n = 17) or cholangitis (n = 7). Twenty-two patients underwent PTM as first treatment of BS (balloon dilatation or stent placement). We evaluated the primary and secondary patency rate of PTM. In 1 patient, PTM failed because the stricture could not be passed with the guide wire, necessitating conversion to a Roux-en-Y choledochojejunostomy (CDJ). Fourteen patients were treated by percutaneous balloon dilatation from which 8 patients (57.2%) were recurrence-free with a mean follow-up of 61 months. One patient with a patent biliary anastomosis underwent retransplantation for acute rejection. Twelve patients received metallic expandable stent placement as their primary treatment (n = 7) or after failure of balloon dilatation (n = 5). Recurrent stricture was found in 7 cases (58%) and was treated by PTM (n = 6) or surgery (n = 1). The primary patency rate for PTM was 58.8% at 12 months and the secondary patency rate 88.4%, with a mean follow-up of 47 months (median: 44 months). The mortality rate was 3.5% (one death). PTM with balloon dilatation, stent placement, or both, represent a safe method to treat anastomotic BSs after orthotopic liver transplantation (OLT) resulting in a secondary patency rate of 88% at 5 years.


Subject(s)
Catheterization , Cholestasis/etiology , Cholestasis/therapy , Liver Transplantation/adverse effects , Acute Disease , Adolescent , Adult , Aged , Catheterization/adverse effects , Cholestasis/mortality , Drainage/adverse effects , Drainage/methods , Female , Follow-Up Studies , Graft Rejection/surgery , Humans , Male , Middle Aged , Reoperation , Retrospective Studies , Stents/adverse effects , Treatment Outcome
18.
Eur Radiol ; 13(1): 114-7, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12541118

ABSTRACT

The purpose of this study was to assess the usefulness of helical CT in depicting the location of acute lower gastrointestinal bleeding. A three-phase helical CT of the abdomen was performed in 24 patients referred for acute lower gastrointestinal bleeding. The diagnosis of the bleeding site was established by CT when there was at least one of the following criteria: spontaneous hyperdensity of the peribowel fat; contrast enhancement of the bowel wall; vascular extravasation of the contrast medium; thickening of the bowel wall; polyp or tumor; or vascular dilation. Diverticula alone were not enough to locate the bleeding site. The results of CT were compared with the diagnosis obtained by colonoscopy, enteroscopy, or surgery. A definite diagnosis was made in 19 patients. The bleeding site was located in the small bowel in 5 patients and the colon in 14 patients. The CT correctly located 4 small bowel hemorrhages and 11 colonic hemorrhages. Diagnosis of the primary lesion responsible for the bleeding was made in 10 patients. Our results suggest that helical CT could be a good diagnostic tool in acute lower gastrointestinal bleeding to help the physician to diagnose the bleeding site.


Subject(s)
Gastrointestinal Hemorrhage/diagnostic imaging , Intestines/diagnostic imaging , Tomography, Spiral Computed , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Female , Gastrointestinal Hemorrhage/etiology , Humans , Male , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...